President Donald Trump imposed a minimum tariff of 10% on almost all countries, before later suspending the measures ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...

Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Adults with a mental illness experienced weight loss and glycemic benefits with use of a GLP-1 without worsening of mental ...

The second home sits just north of where Eli Lilly is setting up shop in the LEAP District. Property records show the IEDC ...